What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
STAT4d
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
New data from a mid-stage study of an Amgen obesity drug showed that it helped participants lose a substantial amount of weight, but questions about how competitive it could be appear to be ...
Wall Street Journal on MSN3d
Amgen Obesity Drug Cut Weight In Closely Watched Study
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
BioPharma Dive3d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
McKnight's Long-Term Care News2d
CMS’ obesity drug coverage implications for nursing home patients
A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...